A detailed history of Charles Schwab Investment Management Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 137,477 shares of VYGR stock, worth $794,617. This represents 0.0% of its overall portfolio holdings.

Number of Shares
137,477
Previous 134,004 2.59%
Holding current value
$794,617
Previous $1.06 Million 24.08%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.77 - $9.27 $20,039 - $32,194
3,473 Added 2.59%
137,477 $804,000
Q2 2024

Aug 12, 2024

BUY
$7.42 - $10.54 $145,075 - $206,078
19,552 Added 17.08%
134,004 $1.06 Million
Q1 2024

May 08, 2024

BUY
$7.15 - $10.84 $212,462 - $322,110
29,715 Added 35.07%
114,452 $1.07 Million
Q4 2023

Feb 06, 2024

SELL
$6.28 - $8.81 $21,578 - $30,271
-3,436 Reduced 3.9%
84,737 $715,000
Q3 2023

Nov 08, 2023

BUY
$7.55 - $11.25 $23,540 - $35,077
3,118 Added 3.67%
88,173 $683,000
Q2 2023

Aug 09, 2023

BUY
$6.94 - $13.99 $503,906 - $1.02 Million
72,609 Added 583.39%
85,055 $973,000
Q2 2022

Aug 15, 2022

SELL
$4.82 - $10.09 $16,696 - $34,951
-3,464 Reduced 21.77%
12,446 $74,000
Q1 2022

May 13, 2022

BUY
$2.75 - $9.44 $43,752 - $150,190
15,910 New
15,910 $122,000
Q3 2021

Nov 16, 2021

SELL
$2.63 - $4.12 $300,493 - $470,734
-114,256 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$3.94 - $5.44 $199,454 - $275,389
-50,623 Reduced 30.7%
114,256 $472,000
Q1 2021

May 17, 2021

SELL
$4.61 - $9.04 $23,100 - $45,299
-5,011 Reduced 2.95%
164,879 $777,000
Q4 2020

Feb 16, 2021

BUY
$7.15 - $12.28 $19,040 - $32,701
2,663 Added 1.59%
169,890 $1.22 Million
Q3 2020

Nov 13, 2020

BUY
$10.01 - $13.75 $5,495 - $7,548
549 Added 0.33%
167,227 $1.79 Million
Q2 2020

Aug 14, 2020

SELL
$8.05 - $14.21 $317,363 - $560,215
-39,424 Reduced 19.13%
166,678 $2.1 Million
Q1 2020

May 15, 2020

BUY
$6.8 - $14.66 $10,302 - $22,209
1,515 Added 0.74%
206,102 $1.89 Million
Q4 2019

Feb 07, 2020

BUY
$12.82 - $16.85 $67,933 - $89,288
5,299 Added 2.66%
204,587 $2.85 Million
Q3 2019

Nov 08, 2019

BUY
$16.31 - $28.29 $968,357 - $1.68 Million
59,372 Added 42.43%
199,288 $3.43 Million
Q2 2019

Aug 09, 2019

BUY
$19.18 - $27.88 $280,929 - $408,358
14,647 Added 11.69%
139,916 $3.81 Million
Q1 2019

May 14, 2019

BUY
$8.0 - $19.66 $90,152 - $221,548
11,269 Added 9.89%
125,269 $2.4 Million
Q4 2018

Feb 14, 2019

SELL
$8.59 - $18.05 $17,068 - $35,865
-1,987 Reduced 1.71%
114,000 $1.07 Million
Q3 2018

Nov 13, 2018

BUY
$17.11 - $21.74 $246,572 - $313,295
14,411 Added 14.19%
115,987 $2.2 Million
Q2 2018

Aug 08, 2018

BUY
$16.76 - $23.92 $248,869 - $355,188
14,849 Added 17.12%
101,576 $1.99 Million
Q1 2018

May 07, 2018

BUY
$16.16 - $31.31 $156,574 - $303,362
9,689 Added 12.58%
86,727 $1.63 Million
Q4 2017

Jan 17, 2018

BUY
$12.26 - $25.88 $334,085 - $705,230
27,250 Added 54.73%
77,038 $1.28 Million
Q3 2017

Nov 13, 2017

BUY
$8.37 - $20.59 $416,725 - $1.03 Million
49,788
49,788 $1.03 Million

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.